Physician profile
Jill E Gibson
NPI 1417124736
$5,022.75
in general payments reported to CMS, 2019-2025
28 companies · $614 in 2025
The $614 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $552 · 2021: $928 · 2022: $1,311 · 2023: $796 · 2024: $479 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.75 | 2019-2023 | |
| Avion Pharmaceuticals | $891.07 | 2019-2023 | Balcoltra, NP Thyroid 60 |
| Evofem Biosciences, INC. | $659.82 | 2021-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $626.18 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $318.02 | 2022-2025 | |
| Aspira Women'S Health INC | $277.58 | 2022-2024 | Ova1 |
| Agile Therapeutics, INC. | $188.99 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $174.84 | 2024-2025 | Veozah |
| Therapeuticsmd, INC. | $157.42 | 2019-2022 | |
| Organon LLC | $106.06 | 2021-2023 | Nexplanon |
| Pfizer INC. | $99.42 | 2019-2023 | |
| Mission Pharmacal Company | $98.65 | 2019-2023 | Citranatal |
| Lupin INC. | $84.50 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.08 | 2020-2025 | |
| Mylan Pharmaceuticals INC. | $54.56 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $30.27 | 2021-2024 | Intrarosa, Femring |
| Daiichi Sankyo INC. | $26.22 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2025 | Trintellix |
| Sage Therapeutics, LLC | $18.29 | 2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $17.63 | 2023 | |
| Hologic Sales and Service, LLC | $16.86 | 2021 | |
| Coopersurgical, INC. | $16.22 | 2025 | Paragard T 380a |
| Novo Nordisk INC | $14.85 | 2025 | Wegovy |
| Resmed Corp | $14.27 | 2019 | |
| Lilly USA, LLC | $13.91 | 2024 | Zepbound |
| Merck Sharp & Dohme LLC | $12.56 | 2019 | |
| Myovant Sciences INC. | $11.93 | 2021 | |
| Meditrina | $10.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.